The relevant success metrics for AI in drug discovery need to be numbers that matter, rather than contrived proxy measures that primarily optimize for scientific publications rather than actual R&D progress. Ultimately, what truly matters is increasing clinical approval rates, as well as novelty in both modality and mode of action space.